AMGEN INC 8-K
Research Summary
AI-generated summary
Amgen Inc. Names Thomas Dittrich as CFO; Peter Griffith to Retire
What Happened
Amgen Inc. announced that Peter H. Griffith, Executive Vice President and Chief Financial Officer, will retire from the CFO role effective August 31, 2026 and remain employed in a non‑executive EVP capacity through January 31, 2027. The Board approved hiring Thomas Dittrich to join Amgen July 1, 2026 (as a non‑executive EVP) and to assume the role of Executive Vice President and Chief Financial Officer effective September 1, 2026. Dittrich will report to CEO Robert A. Bradway and is expected to relocate from Rotkreuz, Switzerland to Thousand Oaks, California when he becomes CFO.
Key Details
- Retirement/transition dates: Griffith steps down as CFO Aug 31, 2026; remains employed through Jan 31, 2027 and will receive standard company retirement benefits. Dittrich becomes CFO Sept 1, 2026 (onboarding begins July 1, 2026).
- 2026 compensation (Swiss employment): base salary CHF 1,070,000; Global Management Incentive Plan target 100% of base salary.
- Long‑term and one‑time awards: 2026 long‑term awards target CHF 4,500,000 (split among options, RSUs and performance units); one‑time RSU CHF 4,700,000 (vests 25%/yr); one‑time cash bonus CHF 4,000,000.
- Retention and relocation: two‑year retention bonus CHF 5,800,000 (repayable pro‑rata if departure for certain reasons within two years); relocation allowance CHF 250,000 and expatriate benefits; standard severance with benefit multiple = 2x salary + target bonus if terminated (not for cause) within two years.
Why It Matters
This is a planned, board‑approved CFO transition intended to provide continuity in Amgen’s finance leadership. Investors should note the material one‑time and ongoing compensation commitments tied to hiring Dittrich (multi‑million CHF awards, cash bonus and retention pay) as well as potential severance exposure in the first two years; these items could affect near‑term compensation expense. Dittrich brings prior experience as a public‑company CFO (Galderma, Shire) and prior roles at Amgen, which supports a smooth operational transition in finance and investor relations.
Loading document...